Selecting a Pharmaceutical Company from Northeast Asia for Investment Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

Joe Clift, a co-developer and also the managing partner of the private equity firm Blacksmith Partners LLC located in New York, managed his organization’s promising market funds for abundant industries. He intended to add one corporation from Northeast Asia to produce enlargement in his pharmaceutical industry portfolio, and had payed concentration on three exceptional pharmaceutical companies: Takeda Pharmaceutical Company Limited from Japan, Dong-A Pharmaceutical Company Limited from Korea, and Sinovac Biotech Company Limited from China. All three businesses had revealed strong increase in their own respective markets through the years.

Japan, the number one pharmaceutical drug consumer in Asia, was also the second-biggest individual market in the whole world, behind the USA. Japan generated sales of $60 billion, which represented approximately 11 per cent of the global market in 2006. Korea maintained a competitive domestic market share supported by an outstanding national medical insurance system and high research power. Korea was the fourteenth-biggest drug consumer in the world market as of 2008. China, being among the fastest-growing pharmaceutical markets, was the second-largest pharmaceutical drug consumer in Asia. With an ever-growing population of senior citizens in Northeast Asia, the managing associate predicted strong potential growth in these emerging markets in drugs for chronic diseases. Which firm should Clift why, and choose among these three companies?

Selecting a Pharmaceutical Company from Northeast Asia for Investment case study solution

PUBLICATION DATE: September 17, 2012 PRODUCT #: W12196-HCB-ENG

This is just an excerpt. This case is about FINANCE & ACCOUNTING